BioCentury | Jan 5, 2021
Product Development

IRAK4 inhibitor pipeline: Data Byte

...the case of IRAK4, this eliminates the protein’s kinase function and its scaffolding function.R835 from Rigel Pharmaceuticals Inc....
...blocks both IRAK4 and IRAK1 and is in a Phase I trial in healthy volunteers. Rigel...
...– IKAROS family zinc finger 1 (IKAROS) (IKZF1) (LYF1)IRAK4 – Interleukin-1 receptor-associated kinase 4 Danielle Golovin PF-06650808 R835 Pfizer Inc. Rigel Pharmaceuticals Inc. Kymera...
BioCentury | Jul 15, 2020
Product Development

Repurposing hopes for Tavalisse in COVID-19 breathe life into Rigel shares

...Rigel is the latest beneficiary of investor exuberance for COVID-19 plays. Shares of Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) gained...
...cells -- is approved in the U.S. and Europe for adult chronic immune thrombocytopenia (ITP). Rigel...
...of the proportion of hospitalized patients progressing from mild or moderate to severe COVID-19 pneumonia. Rigel...
BioCentury | Jan 7, 2020
Company News

Management tracks: Rhythm, Mirati, Aura, IFM, a16z, Cambrex, Alzheon and more

...chief commercial officer. Before joining the rare disease company, Mayer was EVP and CCO of Rigel Pharmaceuticals Inc....
BioCentury | Dec 21, 2019
Company News

Management Tracks: Ionis promotes co-founder to CSO; Syros adds Celgene vet Alles to board; plus Encoded, Cygnal, Harvard Medical School, Immunitas and more

...Bolster Cancer Pipeline, Expand Services Unit ”). Eldon Mayer resigned as chief commercial officer at Rigel Pharmaceuticals Inc....
BioCentury | Nov 16, 2019
Company News

Novartis gains CHMP support in MS, Cushing syndrome

...excessive daytime sleepiness in patients with narcolepsy and obstructive sleep apnea; and Tavlesse fostamatinib from Rigel Pharmaceuticals Inc....
...primary immune thrombocytopenia. Jonathan Block, Associate Editor Mayzent, siponimod (BAF312) Tavalisse, fostamatinib (r788, tamatinib fosdium, FosD, R406) Novartis AG Genentech Inc. Roche Rigel Pharmaceuticals Inc. Jazz...
BioCentury | Oct 24, 2019
Company News

Management tracks: bluebird's Walsh departing as chief strategy officer; plus JDRF, Akcea, Rigel, Elicio and Progenity

...see "Unexpected Shakeup at Akcea Comes Amid Drug Launches" ). Cancer and rare disease company Rigel Pharmaceuticals Inc....
...and portfolio strategy. Jonathan Block, Associate Editor and Elizabeth S. Eaton, Staff Writer bluebird bio Inc. JDRF Akcea Therapeutics Inc. Rigel Pharmaceuticals Inc. Elicio...
BioCentury | Aug 29, 2019
Distillery Techniques

Single cell metabolic analysis to predict therapeutic response and identify targets for NSCLC

...bemcentinib more potently killed patient cells with elevated glycolysis than those with elevated mitochondrial oxidation. Rigel Pharmaceuticals Inc....
BioCentury | Jan 5, 2019
Finance

Ready to launch

The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record year...
BioCentury | Dec 1, 2018
Product Development

Cell therapy momentum at ASH

...ITP abstracts include data from an open-label extension study of two Phase III trials evaluating Rigel Pharmaceuticals Inc.’s...
...AG (NYSE:NVS), Basel, Switzerland Persimmune Inc., San Diego, Calif. Pfizer Inc. (NYSE:PFE), New York, N.Y. Rigel Pharmaceuticals Inc....
BioCentury | Nov 2, 2018
Company News

Rigel grants Kissei Asian rights to Tavalisse

...and Korea. Rigel said it has the option to co-develop the product in the countries. Rigel...
...in cash up front and is eligible for $147 million in development and commercial milestones. Rigel...
...agency since its founding in 1996. Tavalisse is an oral spleen tyrosine kinase (SYK) inhibitor. Rigel Pharmaceuticals Inc....
Items per page:
1 - 10 of 474
BioCentury | Jan 5, 2021
Product Development

IRAK4 inhibitor pipeline: Data Byte

...the case of IRAK4, this eliminates the protein’s kinase function and its scaffolding function.R835 from Rigel Pharmaceuticals Inc....
...blocks both IRAK4 and IRAK1 and is in a Phase I trial in healthy volunteers. Rigel...
...– IKAROS family zinc finger 1 (IKAROS) (IKZF1) (LYF1)IRAK4 – Interleukin-1 receptor-associated kinase 4 Danielle Golovin PF-06650808 R835 Pfizer Inc. Rigel Pharmaceuticals Inc. Kymera...
BioCentury | Jul 15, 2020
Product Development

Repurposing hopes for Tavalisse in COVID-19 breathe life into Rigel shares

...Rigel is the latest beneficiary of investor exuberance for COVID-19 plays. Shares of Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) gained...
...cells -- is approved in the U.S. and Europe for adult chronic immune thrombocytopenia (ITP). Rigel...
...of the proportion of hospitalized patients progressing from mild or moderate to severe COVID-19 pneumonia. Rigel...
BioCentury | Jan 7, 2020
Company News

Management tracks: Rhythm, Mirati, Aura, IFM, a16z, Cambrex, Alzheon and more

...chief commercial officer. Before joining the rare disease company, Mayer was EVP and CCO of Rigel Pharmaceuticals Inc....
BioCentury | Dec 21, 2019
Company News

Management Tracks: Ionis promotes co-founder to CSO; Syros adds Celgene vet Alles to board; plus Encoded, Cygnal, Harvard Medical School, Immunitas and more

...Bolster Cancer Pipeline, Expand Services Unit ”). Eldon Mayer resigned as chief commercial officer at Rigel Pharmaceuticals Inc....
BioCentury | Nov 16, 2019
Company News

Novartis gains CHMP support in MS, Cushing syndrome

...excessive daytime sleepiness in patients with narcolepsy and obstructive sleep apnea; and Tavlesse fostamatinib from Rigel Pharmaceuticals Inc....
...primary immune thrombocytopenia. Jonathan Block, Associate Editor Mayzent, siponimod (BAF312) Tavalisse, fostamatinib (r788, tamatinib fosdium, FosD, R406) Novartis AG Genentech Inc. Roche Rigel Pharmaceuticals Inc. Jazz...
BioCentury | Oct 24, 2019
Company News

Management tracks: bluebird's Walsh departing as chief strategy officer; plus JDRF, Akcea, Rigel, Elicio and Progenity

...see "Unexpected Shakeup at Akcea Comes Amid Drug Launches" ). Cancer and rare disease company Rigel Pharmaceuticals Inc....
...and portfolio strategy. Jonathan Block, Associate Editor and Elizabeth S. Eaton, Staff Writer bluebird bio Inc. JDRF Akcea Therapeutics Inc. Rigel Pharmaceuticals Inc. Elicio...
BioCentury | Aug 29, 2019
Distillery Techniques

Single cell metabolic analysis to predict therapeutic response and identify targets for NSCLC

...bemcentinib more potently killed patient cells with elevated glycolysis than those with elevated mitochondrial oxidation. Rigel Pharmaceuticals Inc....
BioCentury | Jan 5, 2019
Finance

Ready to launch

The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record year...
BioCentury | Dec 1, 2018
Product Development

Cell therapy momentum at ASH

...ITP abstracts include data from an open-label extension study of two Phase III trials evaluating Rigel Pharmaceuticals Inc.’s...
...AG (NYSE:NVS), Basel, Switzerland Persimmune Inc., San Diego, Calif. Pfizer Inc. (NYSE:PFE), New York, N.Y. Rigel Pharmaceuticals Inc....
BioCentury | Nov 2, 2018
Company News

Rigel grants Kissei Asian rights to Tavalisse

...and Korea. Rigel said it has the option to co-develop the product in the countries. Rigel...
...in cash up front and is eligible for $147 million in development and commercial milestones. Rigel...
...agency since its founding in 1996. Tavalisse is an oral spleen tyrosine kinase (SYK) inhibitor. Rigel Pharmaceuticals Inc....
Items per page:
1 - 10 of 474